QualityStocksNewsBreaks – Skinvisible, Inc. (SKVI) to Enter Pain Management Therapeutics Market through Proposed Merger
Skinvisible (OTCQB: SKVI), a developer of innovative drug delivery technology, recently entered a Letter of Intent (“LOI”) regarding a proposed merger with Quoin Pharmaceuticals. The projected merger would mark the company’s entrance into the pain management therapeutics market. An article discussing the topical and transdermal product development company reads: “Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts…